Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.
Status:
Not yet recruiting
Trial end date:
2023-10-20
Target enrollment:
Participant gender:
Summary
Recently, the pathogenesis of epilepsy is immuno-modulatory and neuro-inflammatory which is
commonly activated in epileptogenic brain regions in humans and is clearly involved in animal
models of epilepsy. Inflammatory mediators in the blood and molecular imaging of
neuro-inflammation could provide diagnostic, prognostic, and predictive biomarkers for
epilepsy, which will be instrumental for patient stratification in future clinical studies.
Dysfunction of the blood-brain barrier (BBB) may be responsible for abnormal neuronal firing.
Disruption of the BBB causes the leakage of serum protein and leucocyte invasion into the
brain. These exogenous inflammatory mediators have the potential to lower seizure thresholds,
which could alter channel sensitivity, neurotransmitter uptake or release, and
glia-associated regulation of extracellular environments, such as potassium concentration.